Figure 1. Summary of Treatment Recommendations for
Patients with SSc-ILD
Systemic Sclerosis-Associated Intersitial Lunch Disease
Treatment
Recommendations
Cyclophosphamide Rituximab
Nintedanib
Nintednaib plus
Mycophenolate
Tocilizumab
RESEARCH RECOMMENDATION
Pirfenidone plus
Mycophenolate
Pirfenidone
CONDITIONAL IN FAVOR
STRONG IN FAVOR
Mycophenolate
